The humanised monoclonal antibody targeting CD40 (SGN-40) induces potent antitumour effects when tested on CD40-positive tumour cell lines representing a variety of haematologic malignancies (Tai et al, 2004; Law et al, 2005). This evidence concerns the gene CD40 and neoplasm.